Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | G6PD | P11413 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL621605 | 1.00 | C5AR1 (0.40) | C5AR1DHODHNPSR1TLR9CYP24A1 | |
| SCHEMBL578874 | 1.00 | C5AR1 (0.40) | C5AR1DHODHNPSR1TLR9CYP24A1 | |
| SCHEMBL3744998 | 0.84 | C5AR1 (0.38) | C5AR1DHODHNPSR1TLR9GAA | |
| SCHEMBL27358566 | 0.83 | C5AR1 (0.39) | C5AR1DHODHNPSR1TLR9CYP24A1 | |
| SCHEMBL15668772 | 0.82 | C5AR1 (0.37) | C5AR1DHODHNPSR1TLR9CYP24A1 | |
| SCHEMBL32668915 | 0.82 | CA2 (0.40) | C5AR1DHODHNPSR1TLR9CYP24A1 | |
| SCHEMBL15668771 | 0.82 | C5AR1 (0.37) | C5AR1DHODHNPSR1TLR9CYP24A1 | |
| SCHEMBL32668708 | 0.82 | CA2 (0.40) | C5AR1DHODHNPSR1TLR9CYP24A1 | |
| SCHEMBL17542475 | 0.81 | C5AR1 (0.38) | C5AR1DHODHNPSR1TLR9CYP24A1 | |
| SCHEMBL10932836 | 0.81 | GBA1 (0.46) | TLR9CYP24A1GAAALDH1A1GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024529-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230271981-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-08-31 | — | — | US | disclosed |
| US-11685747-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2023-06-27 | — | — | US | disclosed |
| EP-3601297-B9 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC (US) | 2023-05-24 | — | — | EP | disclosed |
| EP-3601297-B1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC (US) | 2022-10-19 | — | — | EP | disclosed |
| US-11224601-B1 | Compounds that inhibits MCL-1 protein | AMGEN INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-11001598-B2 | Compounds that inhibit Mcl-1 protein | AMGEN INC. (US) | 2021-05-11 | — | — | US | disclosed |
| US-20210040120-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2021-02-11 | — | — | US | disclosed |
| US-10836779-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-10821115-B2 | Compounds that inhibit Mcl-1 protein | AMGEN INC. (US) | 2020-11-03 | — | — | US | disclosed |
| EP-2253616-A1 | Process for the preparation of compounds capable of activating cholinergic receptors | Targacept, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20100121061-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100121061-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20060293289-A1 | Compounds Capable of Activating Cholinergic Receptors | CALDWELL WILLIAM S | 2006-12-28 | — | — | US | disclosed |
| US-7045538-B2 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-6979695-B2 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. (US) | 2005-12-27 | — | — | US | disclosed |
| EP-1556352-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | Targacept, Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20050148611-A1 | Compounds capable of activating cholinergic receptors | CALDWELL WILLIAM S (US) | 2005-07-07 | — | — | US | disclosed |
| WO-2004031151-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2004-04-15 | — | — | WO | disclosed |
| US-20030125345-A1 | Nicotinic compounds; treating central nervous system disorders | TARGACEPT, INC. | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10821115-B2 | Compounds that inhibit Mcl-1 protein | MCL1, BCL9, BCL2L1 | C5AR1 3403/4885DHODH 3104/4885NPSR1 4654/4885 |
| US-11001598-B2 | Compounds that inhibit Mcl-1 protein | MCL1, BCL2L1, BCL9 | C5AR1 3754/4885DHODH 2817/4885NPSR1 4714/4885 |
| US-20050148611-A1 | Compounds capable of activating cholinergic receptors | CHRM3, CHRM5, CHRM4 | C5AR1 259/4885DHODH 1423/4885NPSR1 31/4885 |
| US-20230271981-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL2L1, BCL9 | C5AR1 3754/4885DHODH 2817/4885NPSR1 4714/4885 |
| US-11685747-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL2L1, BCL9 | C5AR1 3754/4885DHODH 2817/4885NPSR1 4714/4885 |
| US-20030125345-A1 | Nicotinic compounds; treating central nervous system disorders | SLC6A2, CHRNA6, CHRNA10 | C5AR1 1287/4885DHODH 892/4885NPSR1 40/4885 |
| US-12024529-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL2L1, BCL9 | C5AR1 3754/4885DHODH 2817/4885NPSR1 4714/4885 |
| US-20100121061-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | CHRM3, CHRM5, CHRM4 | C5AR1 259/4885DHODH 1423/4885NPSR1 31/4885 |
| US-20210040120-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL2L1, BCL9 | C5AR1 3754/4885DHODH 2817/4885NPSR1 4714/4885 |
| US-20060293289-A1 | Compounds Capable of Activating Cholinergic Receptors | CHRM3, CHRM5, CHRM4 | C5AR1 259/4885DHODH 1423/4885NPSR1 31/4885 |
| US-10836779-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | C5AR1 3674/4885DHODH 3319/4885NPSR1 4685/4885 |
| US-11224601-B1 | Compounds that inhibits MCL-1 protein | MCL1, BCL9, BCL2L1 | C5AR1 3453/4885DHODH 3117/4885NPSR1 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.